Hypothesis

Aged skeletal stem cells (SSCs) release high‑mobility group box 1 (HMGB1) that activates TLR4 on bone‑marrow monocytes, sustaining a TNF‑ and IL‑6‑rich niche. This cytokine milieu induces suppressor of cytokine signaling 3 (SOCS3) in erythroid progenitors, which blocks JAK2‑STAT5 phosphorylation downstream of EPO, producing EPO resistance and anemia.

Mechanistic rationale

• HMGB1 is a canonical damage‑associated molecular pattern that signals through TLR4 to drive NF‑κB‑dependent transcription of pro‑inflammatory cytokines https://doi.org/10.1038/nri2255.
• Aged SSCs exhibit a senescence‑associated secretory phenotype (SASP) that includes HMGB1 release, a feature not yet linked to the erythropoietic niche https://doi.org/10.1016/j.cell.2020.05.018.
• SOCS3 directly inhibits JAK2 kinase activity and STAT5 docking, a mechanism demonstrated in EPO‑dependent erythroid differentiation https://doi.org/10.1182/blood-2005-02-0584.
• Thus, the HMGB1‑TLR4‑SOCS3 axis provides a parsimonious link between stromal aging and intrinsic erythroid signaling defect.

Testable predictions

1. Genetic or pharmacological reduction of HMGB1 in SSCs (e.g., using SSC‑specific Cre‑Hmgb1 knockout or neutralizing anti‑HMGB1 antibody) will lower monocyte TNF‑α and IL‑6 production in aged marrow.
2. Consequently, erythroid progenitors from treated mice will show restored STAT5 phosphorylation after EPO stimulation and increased hemoglobin synthesis in vitro.
3. In vivo, aged mice receiving SSC‑targeted HMGB1 blockade will exhibit higher reticulocyte counts and serum hemoglobin without changes in systemic EPO levels.
4. Conversely, TLR4 activation in young SSCs (via LPS low‑dose or HMGB1‑containing exosomes) will recapitulate the aged niche phenotype, inducing SOCS3 in progenitors and impairing erythropoiesis.

Experimental approach

• Use Pdgfra‑CreERT2;Hmgb1^fl/fl mice to delete HMGB1 specifically in SSCs of 20‑month‑old animals. Controls receive tamoxifen‑treated Pdgfra‑CreERT2;Hmgb1^wt/fl littermates.
• At 2 weeks post‑induction, isolate bone‑marrow mononuclear cells and perform flow cytometry for monocyte subsets (Ly6C^hi, Ly6C^lo) and intracellular TNF‑α/IL‑6.
• Culture mononuclear cells with recombinant EPO (2 U/mL) for 48 h, then phospho‑STAT5 (Y694) measured by phospho‑flow.
• In parallel, assay erythroid colony‑forming units (CFU‑E) and hemoglobin content via o‑dianisidine staining.
• Serum hemoglobin, hematocrit, and reticulocyte percentage assessed via automated hematology analyzer.
• For gain‑of‑function, inject young mice with exosomes purified from aged SSC culture (characterized by HMGB1 enrichment via western blot) and repeat the above readouts.

Potential outcomes and interpretation

• If SSC‑specific HMGB1 loss normalizes monocyte cytokine output, rescues STAT5 phosphorylation, and improves erythropoietic metrics, the hypothesis is supported.
• No change would falsify the HMGB1‑TLR4‑SOCS3 link, prompting investigation of alternative SASP factors (e.g., IL‑1α, CCL2).
• Exosome‑mediated phenocopy in young mice would further cement the sufficiency of SSC‑derived HMGB1 in driving niche inflammation.

Implications

Targeting the HMGB1‑TLR4 axis in stromal cells offers a strategy distinct from EPO supplementation, addressing the root cause of age‑related anemia. It also suggests that senomorphic or senolytic approaches focused on SSC SASP could be combined with low‑dose EPO for synergistic benefit in elderly patients.